Molecular characterisation of oligometastatic disease

This project focuses on validating the existence of an oligometastatic (OM) subset of early metastatic disease and on defining its molecular phenotype by using multispectral immunofluorescence. Our working hypothesis is that OM represents an early metastatic phase, which is potentially curable. Defining the OM phenotype is a critical requirement in the selection of candidates for a curative attempt. This project is being performed in collaboration with the Department of Radiation Oncology of the Champalimaud Clinical Centre (CCC).